Abstract:
PURPOSE: A composition containing 3-methyladenine is provided to decompose neutral lipid into glycerol and free fatty acid and to prevent or treat obesity, diabetes, and hyperlipidemia. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains 3-methyladenien as an active ingredient. 3-methyladenine decomposes neutral lipid into glycerol and free fatty acid. A food composition for preventing or treating obesity contains 3-methyladenine as an active ingredient. The composition is used for preventing or treating obesity-associated metabolic diseases including diabetes, arteriosclerosis, metabolic diseases, and hyperlipidemia. The pharmaceutical composition is manufactured in the form of a liquid formulation or parenteral formulation.
Abstract:
PURPOSE: A composition containing genistein or pharmacologically acceptable salt thereof is provided to suppress fractalkine expression and vascular inflammation. CONSTITUTION: A composition for treating vasculitis caused by fractalkine expression contains 1-10 wt% of genistein or pharmacologically acceptable salt thereof as an active ingredient. The composition is a pharmaceutical composition or food additive composition. The composition also contains NF-kappaB inhibitor and p38 inhibitor or PI3'-K inhibitor in a weight ratio of 1:10-10:1.
Abstract:
PURPOSE: A composition containing euphobiasteroid is provided to effectively suppress the differentiation of induced adipocytes and to prevent or treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains euphobiasteroid as an active ingredient. A food composition for preventing or treating obesity contains euphobiasteroid as an active ingredient. Euphobiasteroid is isolated from Euphorbiae Lathyridis semen using a solvent. The solvent is water, anhydrous or hydrous low alcohol of 1-4 carbon atoms(methanol, ethano, propanol, butanol), mixture solvent of low alcohol and water, acetone, ethyl acetate, chloroform, or 1,3-butylene glycol.
Abstract:
본 발명은 마우스의 간 조직에서 특이적으로 발현되는 MML2(Mus musculus Liver 2) 단백질, 상기 단백질을 코딩하는 유전자, 상기 유전자 또는 상기 단백질에 대한 항체를 포함하는 간 관련 질병을 진단하기 위한 마이크로어레이, 상기 유전자에 대한 프라이머로 이루어진 간 관련 질병을 진단하기 위한 프라이머 세트, 상기 프라이머 세트를 포함하는 간 관련 질병을 진단하기 위한 키트 및 상기 프라이머 세트를 이용하여 포유류의 간 관련 질병을 진단하는 방법에 관한 것이다. 간 특이적 유전자, MML2 단백질, 마이크로어레이, 프라이머 세트, 키트
Abstract:
PURPOSE: A product image service method and apparatus thereof are provided to supply a product image of the identical size to a user regardless of the kinds of a web browser. CONSTITUTION: A service management block(1063) draws out product menu screen data from product database(1069). A rate calculation block(1065) actually calculates the size ratio of the product. An image resizing block(1067) resizes the real thing size image of the corresponding product based on the size rate calculation value.
Abstract:
본 발명은 상엽 추출물, 이의 다이클로로메탄 분획물 또는 이로부터 분리된 활성분획물 또는 퍼퓨린-7 디메틸 에틸에스테르, 하이드록시-페오포르바이드 A 에틸에스테르, 페오포르바이드 A 에틸에스테르, 디데하이드로-로도클로린 에틸메틸에스테르, 하이드록시 페오포르바이드 A 메틸에스테르 또는 페오포르바이드 A 메틸에스테르 또는 이들의 혼합물을 유효성분으로 함유하는 식욕 억제, 우울증의 예방 및 개선, 또는 불안증의 예방 및 개선용 식품 조성물에 관한 것이다. 본 발명에 따른 조성물은 멜라닌 농축호르몬 수용체 아형-1(Melanin Concentration Hormone receptor subtype-1, MCH-1)과의 강한 길항적 작용을 나타내어 식욕억제효과, 체중감소효과 등을 나타내므로 식욕 억제, 우울증의 예방 및 개선, 또는 불안증의 예방 및 개선에 유용하게 사용될 수 있다. 상엽 추출물, MCH, 비만, 퍼퓨린-7 디메틸 에틸에스테르, 페오포르바이드 A 에틸에스테르, 하이드록시-페오포르바이드 A 에틸에스테르
Abstract:
본 발명은 3-하이드록시-3-메틸글루타릴 보조효소 A 환원효소 저해용 펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장 질환 및 심혈관계 질환 치료제에 관한 것으로, 더욱 상세하게는 3-하이드록시-3-메틸글루타릴 보조효소 A 환원효소의 경쟁적 저해제로 작용하는 펩타이드를 디자인하고, 상기 펩타이드를 이용한 3-하이드록시-3-메틸글루타릴 보조효소 A 환원효소 저해제 및 고콜레스테롤로 인한 심장 질환 및 심혈관계 질환의 치료제에 관한 것이다. 고콜레스테롤혈증, 경쟁적 저해제
Abstract:
A peptide, an inhibitor for 3-hydroxy-3-methylglutaryl coenzyme A reductase, and an therapeutic agent containing the peptide are provided to treat the heart disease and cardiovascular disease due to high cholesterol. A peptide has the sequence represented by the sequence number 1, the sequence number 2, the sequence number 3, the sequence number 4, the sequence number 5, the sequence number 6, the sequence number 7, the sequence number 8 or the sequence number 9. An inhibitor for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase contains the peptide.
Abstract:
A method of making a barley extract using super critical fluid extraction is provided which allows for mass production of barley tea. The product contains characteristic flavor of barley and can be used as a functional beverage such as barley soybean milk, barley beverage, barley milk, etc. Carbon dioxide is passed through a freezer, filtered with a filter(1) and supplied to an extraction tank(4) through a compressor(2) with a flow regulator(3) to extract barley under a pressure of 300 to 400bar. Thereafter, the barley extract is sent to a separation tank(8) with a safety plate(5), a back pressure regulator(6), a heater(7) and a temperature controller(CT). In the extraction process, the barley is roasted, ground to a size of 1 to 5mm and then extracted at 30 to 45deg.C for 2 to 4hr. The barley extract obtained is dissolved in ethanol and added to conventional drinks in an amount of 0.5 to 5%.